Free provider profile
PAOLO TROIA-CANCIO, M.D.
ELK GROVE, CA
Find similar providers: Internal Medicine in ELK GROVE, CA
Practice contact details
Source: CMS NPPES · published practice information
Practice phone
916-683-3955
Fax
916-683-7290
Practice address
8110 LAGUNA BLVD, ELK GROVE, CA, 95758
- Registry updated
- 2021-10-28
- NPI issued
- 2005-11-15
- RepVector retrieved
- 11/21/2026
A recent retrieval can still contain an old address if the provider has not updated their registry record. Website email checks show their own date under Find email.
Specialties & registration
CMS NPPES taxonomy classifications · not verification of certification or services offered
Internal Medicine
207R00000X
PrimaryInternal Medicine, Infectious Disease
207RI0200X
1 registered practice location · A registry listing does not establish active practice, referral relationships or insurance participation.
Need more providers like PAOLO TROIA-CANCIO?
See the count and top 3 free, ranked by Medicare billing. Full list $29, included with membership.
Rep intel
What PAOLO TROIA-CANCIO prescribes and who else does
Top Medicare Part D drugs by claims (public CMS data):
- Eliquis
- Ozempic
- Biktarvy
- Tivicay
- Triumeq
See all internal medicine physicians in CA who bill Medicare →
Your next referral list starts here
Provider + market indicator
A combined screening indicator—not a provider fraud-risk score. Local plan ratings describe the surrounding market, not this provider’s quality, plan membership or wrongdoing.
Comparing current CMS billing with peers and checking OIG and plan ratings… A new peer comparison can take about a minute.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
10,027
Medicare patients
702
Part D drug cost
$2,550,260
Brand-name share
15.3%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Biktarvy (Bictegrav/Emtricit/Tenofov Ala) | 77 | $345,171 |
| Triumeq (Abacavir/Dolutegravir/Lamivudi) | 53 | $200,203 |
| Tivicay (Dolutegravir Sodium) | 60 | $171,208 |
| Promacta (Eltrombopag Olamine) | 12 | $149,805 |
| Eliquis (Apixaban) | 125 | $138,635 |
| Descovy (Emtricitabine/Tenofov Alafenam) | 47 | $122,365 |
| Ozempic (Semaglutide) | 103 | $116,136 |
| Odefsey (Emtricitab/Rilpiviri/Tenof Ala) | 29 | $96,689 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Latest Medicare Part B billing
CMS Physician and Other Practitioners, by Provider and Service. New published billing years are detected daily, using the same release as the Billing analyst and risk maps.
Loading the latest published CMS billing file…
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
Checking Open Payments…
Industry payments across CA — which companies pay providers there.
Open Payments page for this provider
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.
